Sutro Biopharma, Inc. is a biotechnology company focused on clinical stage drug discovery, development, and manufacturing. The company specializes in precisely designed cancer therapeutics, as self-described.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

COM:SUTROBIO

Sutro Biopharma, Inc.

Last Close

2.67

21/11 16:07

Market Cap

294.46M

Beta: -

Volume Today

366.79K

Avg: -

locale

market

industry

website

ipo date

peer of

competitor of

Metrics